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1. Introduction 
 
Macroeconomic policy requirements, including the need to control inflation and avoid 
large-scale public deficit, may limit the capacity of financial policy-makers at the country 
level to allocate sufficient resources for scaling up access to HIV prevention, care and 
treatment. National authorities may have concerns about policies that may lead to increased 
long term dependence on external donor financing. In addition, international and bilateral 
donor agencies may themselves have concerns about targeting an increasing share of 
Official Development Assistance (ODA) toward AIDS programmes rather than to other 
policies aimed at promoting economic growth, poverty reduction and public health in 
developing countries.
1
 
 
Since the early years of the HIV pandemic, macroeconomic modelling has been used to 
assess its potential impact on economic growth in the most affected countries, notably in 
Sub-Saharan Africa.
2,3,4
 New economic models derived from the theory of endogenous 
growth
5,6,7,8
 emphasize the importance of human capital in economic growth and take into 
account the way by which the HIV pandemic may affect economic agents in the long term 
(e.g. investment in education or physical capital, savings, etc.).
9,10,11,12
  
 
Here we present an analysis based on the use of such an endogenous growth model aimed 
at comparing the potential macroeconomic impact of AIDS in six African countries in the 
presence and in the absence of scaling up access to HIV treatment. Our results provide a 
macroeconomic rationale to the current efforts of increasing funding for AIDS programmes 
with the aim of reaching universal access to treatment by 2010.
1
 Our analysis should 
further contribute to the on-going international debate on the extent to which new funds 
should be devoted to health systems in general and, more specifically, to the response to the 
HIV epidemic.  
 
2. Material & methods 
The endogenous growth CGE-Model  
The model used for this research is a Computable General Equilibrium Model (CGE-Model), 
including an endogenous growth property. Table 1 presents the various channels through 
which the AIDS pandemic may affect economic growth as well as the list of variables used in 
the model to capture these effects.  
 
Insert TABLE 1 
 
The model assumes the following macroeconomic production function: 

 )),(.()),(.(.)),(()( yDyHLyKY   
with  , population's epidemiological status and 1     . 
This equation will serve to analyse the effect of the epidemic on the macroeconomic income 
of a country. Any increase in   represents a deterioration of the population's health status and 
affects the accumulation process of each production factors (Y, K, L, H and D, as defined in 
Table 1). A specificity of the model (its “endogenous growth” property) is that these 
cumulative factors, and consequently the total growth rate of the economy, are an increasing 
function of the per capita national income level Y/N (=y), with a critical value threshold yc 
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that has to be reached in order to obtain positive growth (growth rate G > 0 for y > yc). The 
exact threshold level and the calculation of the macroeconomic rate of growth are based on 
microeconomic foundations which take into account agents’ behaviours including at the 
household level. An precise mathematical appendix (available on request) gives more details 
about the microeconomic hypotheses used about agents’ behaviours and also explains the 
fundamental reasons why the existence of the threshold level yc might be at the origin of 
substantial differences between countries in the assessment of the policy response.  
 
The scenarios 
The empirical calibration of the model had two aims: to assess the macroeconomic benefits of 
the policy aimed at scaling-up access to HIV treatment and to help identifying conditions 
under which such policy will be efficient in the specific context of a country, including its 
current level of growth. Similarly to previous assessments of the macroeconomic impact of 
AIDS,
11,12
 the model calculates, for each country to which it is applied, the difference between 
the simulated GDP in a baseline scenario “without AIDS” (that is, prevalence HIV rate set at 
zero) and in an alternative macroeconomic pathway “GDP with AIDS”. However, contrary to 
previously used models, in our application, we also recalculate this difference when 
introducing a new scenario including a policy response to the epidemic based on scaling up 
access to HIV treatment. 
 
As in other researches,
13
 we made the choice to “represent” the policy response through a 
decrease in prices of the healthcare commodities which are needed to deliver an essential 
package of care for the HIV-infected population, including drugs for antiretroviral treatment. 
Results are presented below under the hypothesis that the totality of the set of goods 
contributing to health expenditures for HIV care and treatment has its price reduced by 50% 
during the 2003-2006 period and remains stable until 2010. We performed however extensive 
sensitivity analysis testing alternative levels of reductions of the price index of these 
healthcare goods from only 10 % to 90%.  
 
More specifically, the policy response is represented in the model through the following 
pathway: a reduction of the healthcare price index has the direct effect of increasing demand 
for healthcare and facilitating access by reducing households’ financial constraints; 
consequently, the heath-status and the well-being of each HIV-infected individual improve 
(this effect is expected by households; it is the motivation for their healthcare demand). Two 
additional effects are also calculated by the model: healthcare consumption has a positive 
effect on the ratio active population/total population (L/N) and consequently implies a direct 
quantitative increase in the productivity of the population; in addition, increase in healthcare 
consumption for HIV care and treatment will also improve the future workers’ efficiency via 
an improvement of human capital H (this qualitative effect increases the intrinsic productivity 
of the population).
14
 In other words, the model takes into account the fact that more healthy 
people can 
i) participate to the production with a greater likelihood 
ii) work better, now and in the future, as their (good) health status facilitates effort 
and concentration as well as acquisition and transmission of knowledge and 
savoir-faire to others, including their own children. 
The importance of these two effects has already been emphasized in the theoretical 
literature
15,16
 but, to our knowledge, in the case of measuring the potential macroeconomic 
impact of the Aids epidemic, both effects have not previously been taken into account in a 
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simultaneous way by a computable macroeconomic model, using an endogenous growth 
framework. Of course, it must be noted that our scenarios use a simplified assumption 
according to which “good health” directly translates into improved human capital. Such 
assumption de facto favours some specific channels through which AIDS affects labour 
productivity: it insists on the direct effect, through workforce assiduity, capacity or savoir-
faire,
2,9
 rather than on the indirect effect through intergenerational transfers of education.
11
 
The transformation of medicines in “good health”, and then in human capital, is also 
conditioned by the effective success in the scaling up of HIV treatments (medical feasibility, 
efficiency in the supply-chain delivering medicines to the whole territory). The results of the 
macro model are dependant on these hypothesized scenarios. 
 
 
The empirical data used 
The model was applied to a panel of six African countries: Angola, Benin, Cameroon, Central 
African Republic and Ivory Coast. The model was calibrated using UNAIDS epidemic 
projections (by SPECTRUM EPP – Epidemic Projection Package – software) as well as 
available national data for GDP, population, capital stock, gross domestic investment, fiscal 
policy, etc., up to 2003 –extracted from World Development Indicators (WDI, from the World 
Bank). The value “epsilon”, rate of prevalence, is forecasted dynamically by the SPECTRUM 
model, for each year and each country (2000-2010). These prevalence rates and the 
demographic projections used in the study are imported from U.N. databases and are not 
endogenous to the macroeconomic model (a weakness that we address in the discussion 
section). An important unobservable variable is the « human capital », H, at the beginning of 
the period (1985); it has been determined as the best econometric fit of the observed 
macroeconomic level of GDP growth during the 1985-1995 period,
17
 whereas the consecutive 
variations of H have been endogenously determined by the model. In addition, parameters 
such as elasticity of healthcare demand to price and to income, have been obtained from 
previous surveys about health care demand and expenditures in African countries.
18,19
 
 
3. Results 
Figure 1 and Table 2 first show for each country the impact of the epidemic on GDP in the 
absence of scaling up access to ART (GDP versus GDP no AIDS). In spite of the variability 
of their HIV prevalence rates, the detrimental impact of AIDS on GDP, i.e. the difference in 
GDP when comparing the scenarios with and without AIDS, is in the same order of 
magnitude in four countries : Angola, Centre African Republic, Cameroon and Ivory Coast: in 
these countries, the GDP in 2010 will be respectively 12.8%, 13.9%, 17.0%, and 13.3% lower 
than it would have been in the absence of the HIV/AIDS epidemic –corresponding 
approximately to a 1% loss in GDP growth per year through the 2000-2010 period. The two 
countries with respectively the lowest and highest HIV prevalence rates present a contrasting 
picture: the impact is a lot more limited in the case of Benin (-4.2% in 2010), whereas on the 
contrary, Zimbabwe is the most dramatically affected (-25.5%).  
 
Insert TABLE 2 AND FIGURE 1 
  
Table 2 and Figure 1 also depict the potential macroeconomic impact of scaling up access to 
HIV care and treatment. Table 2 and Figure 1 demonstrate that scaling-up access to treatment 
in the affected population of workers would significantly limit GDP losses due to AIDS from 
a 24.8% reduction in GDP loss in Central African Republic to a 85.2% reduction of the GDP 
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loss in Angola, with Cameroon and Ivory Coast respectively presenting 32.9 and 32.1% 
reductions. Quite interestingly in the case of Benin, the least affected country in our sample, a 
massive response would allow to re-establish a rate of growth similar to the one which would 
have been expected in the absence of AIDS. To the contrary, Zimbabwe does not seem to 
strongly react to scaling up with only a limited 10.3% reduction in GDP loss. Finally, Table 2 
shows that for four out of the six countries (Angola, Benin, Cameroon, Ivory Coast), the 
macroeconomic gains of scaling up would become potentially superior to its associated costs 
in 2010. At this date, these countries could de facto self-finance their program.  
 
When testing alternative levels in the scaling up response, through various hypotheses in the 
price index for healthcare goods, it appears that in order for Cameroon, Central African 
Republic, and Ivory Coast to achieve at least a two third reduction in GDP losses (as was 
already the case for Benin and Angola under the hypothesis of a 50% decrease in the price 
index) further reductions in price –up to 70%– would be needed. This would remain an 
unattainable goal for Zimbabwe, even in the hypothesis of a 90% decrease.  
 
4. Discussion 
The present study is the first attempt to apply macroeconomic modelling, using an 
endogenous growth framework that incorporates the long term effects on human capital, to 
forecast the impact of HIV/AIDS on economic growth in some of the most affected sub-
Saharan African countries, as well as the potential mitigating effect of scaling up access to 
antiretroviral treatment. Early macro-economic estimations forecasted a one-point reduction 
in the rate of growth of national wealth for countries with HIV prevalence above 5%. 
12,13,20,21,22
 Our results also point out a 1% loss in GDP growth per year due to AIDS in four of 
the Sub-Saharan countries studied but better capture the potential detrimental impact of such 
yearly losses on the long-term growth of these economies. As it seems to be already the case 
for Zimbabwe, and as it would threaten to be the case in Angola, Cameroon, Central African 
Republic and Ivory Coast in the absence of an appropriate response, there is a significant risk 
that the long term impact of AIDS may drive the economy to an “epidemiological trap” that 
could reverse the development process. Similar long term pessimistic predictions in the 
absence of response had previously been obtained in the case of South Africa.
 10,11,23  
 
Of course, this study shares some limitations with most available models for evaluating the 
macroeconomic impacts of shocks. In any case our model should be considered as an 
evaluation of the impact of current programs, it is rather an attempt to simulate the potential 
economic gains that may be expected from scaling up to the extent that resources are used in 
an “ideally” efficient way. Indeed, the model predicts an optimal evolution under the 
hypothesis that both health programs and production factors in the economy (physical capital, 
labour and public spending) are used without local shortages and in a fully-efficient way. The 
no-AIDS baseline scenario therefore neglects the fact that some other impediments for growth 
could affect African countries (governance problem, civil war, under-employment, structural 
unbalances due to a post-colonial heritage).
24,25
 We also do not take into account other 
negative or positive shocks (e.g. fluctuation in prices of raw materials) which may explain 
random deviations of the economy from its long-term growth path, as well as some aspects 
related to the informal economy (black market) and possible flows of labour between formal 
and informal sectors. In addition, an emphasis on GDP, which is the focus of macroeconomic 
modelling, underestimates the whole consequences of the HIV epidemic on the unpaid non-
market activities that are of prime importance for human development in the developing 
world.
26,27,28,29
 The introduction of human capital, through the use of an endogenous growth 
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model, allows, however, taking into account some of these effects, e.g. the transmission of 
knowledge and savoir-faire. 
 
Another set of limitations relates to the possible shortcomings of the empirical data used. 
Whereas the main parameters used to calibrate the model are available in existing 
macroeconomic databases from the World Bank, some specific values used in the 
microeconomic component of the model were available for one country alone and 
extrapolated to the others. Two specific limitations of our research should further be 
recognized. First, our simulations of the impact of scaling up treatment do not take into 
account how the increased availability of treatment may modify the dynamics of HIV 
transmission in the long run. It can be argued that combining treatment with effective 
prevention efforts could reduce the resource needs for treatment dramatically in the long 
term.
30,31
 Mathematical epidemiologic models indicate however that the decreased 
infectiveness of treated patients is likely to be counterbalanced by the increase in life 
expectancy of the patients that will predictably translate into an increased probability of 
sexual encounters between sero-different partners.
32,33
 A recent epidemiological modelling 
even concluded that antiretroviral treatment cannot be seen as a direct transmission prevention 
measure, regardless of the degree of coverage.
34
 Thus, the overall impact of scaling up access 
to treatment on HIV incidence will further depend on the extent to which availability of 
treatment will affect individual and group HIV-related risk behaviours,
35,36,37
 as well as 
behaviours toward seeking HIV screening and care in the subpopulation who is already 
infected.
38,39
  
 
Second, as in previous macroeconomic exercises,
13
 we introduced the policy option of scaling 
up treatment in our model based on the hypothesis of a decrease in price of the health care 
commodities that are part of an efficient HIV package of care. The extent to which such an 
assumption may be realistic remains a matter of debate. A 50% or more reduction in prices for 
the HIV package of care may be obtained through the implementation of differential 
pricing
40,41
 and subsidies from international ODA (which would limit the direct contribution 
of both public funds from national budgets and out-of-pocket payments from affected 
households). Prices remain high for second line antiretroviral drugs and other components of 
care such as tests, diagnostic kits and laboratory monitoring tools. There are thus still 
windows of opportunity for further decreases in prices of goods and services related to the 
HIV package of care. However, if the goal of universal access to treatment is to be achieved 
in 2010, the global production capacity of antiretroviral drugs and other commodities for 
efficient HIV care delivery will need to be multiplied by a factor of ten over the next five 
years, which raises a number of challenges for brand-name and generic pharmaceutical 
manufacturers and for health care systems that may limit decreases in prices. 
 
Our approach explicitly focuses attention on the importance of timing in the policy response. 
Delays may have irreversible effects. If the AIDS-shock has already driven the economy close 
to a no-development trap, the policy response, including access to treatment, may be efficient 
in restoring the dynamics of growth, if and only if its implementation is carried out at a rapid 
and massive scale. Then, our results not only confirm that the long term effects of the HIV 
epidemiologic shock have been underestimated, notably its deferred impact on the 
productivity of the future generations through the deterioration of the human capital. The 
study also points out that a country’s proximity to a threshold level –which, if it is not 
attained, could reverse the whole development process– is a key parameter for the potential 
impact of the epidemic on growth. In spite of the methodological limitations discussed above, 
our approach strongly suggests that a massive investment in scaling-up access to HIV 
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treatment may efficiently counter-act the detrimental long term impact of the HIV pandemic 
for growth in Sub-Saharan Africa, and that potential macroeconomic benefits of scaling up 
may even compensate for its associated costs in some of the most affected countries at the 
2010 horizon. For such a success to be achieved, knowing that all countries have an 
adjustment period lasting a minimum of 5 years, a massive external aid should enter the 
country in the very beginning of the period, not only in order to help buying treatments but 
also in order to reinforce the capacity of the national health systems and to avoid possible 
local shortages in delivery of HIV services.  
 
In its report to the G8 Gleneagles Summit of July 2005, the Commission for Africa, a group 
of seventeen prominent experts in the field, advocated an immediate doubling of current ODA 
targeted to Sub-Saharan Africa for the 2006-10 period.
42
 In the more realistic estimates, an 
implementation of the Commission’s recommendation would imply 10 billion US $ of extra-
annual aid for health and HIV/AIDS. This alone would cover about half of the total direct 
costs of the scaling up policy that was assessed in our macroeconomic simulation, if we 
extrapolate our scenario in the six studied countries to the whole Sub-Saharan African region. 
Strong uncertainties however remain on the amounts of international aid that will be targeted 
to scaling up access to HIV treatment in the coming years, including the future prospects of 
funding of the Global Fund against AIDS, Tuberculosis & Malaria. Our estimation of the 
positive macroeconomic potential impact of scaling up access to HIV treatment provides a 
strong indication that massive efforts to scale up these programs is a rational investment for 
both national governments and the international donor community. 
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